Rapid diagnostics

A test diagnoses COVID-19 virus in 30 minutes

A new diagnostic test can detect the RNA of SARS-CoV-2, the virus that causes COVID-19, in urine, blood, saliva or mouth swab samples in just 30 to 45 minutes, according to a new study in the open-access journal PLOS ONE by Laura Lamb of the Beaumont Health System, Michigan, USA, and colleagues.

Photo
Detection of SARS-CoV-2 with RT-LAMP in patient nasopharyngeal swab samples with RNA isolation.
Source: Lamb et al, 2020 (PLOS ONE, CC BY)

SARS-CoV-2 is difficult to diagnose early in infection as patients may be asymptomatic or have mild, non-specific symptoms. The current standard for diagnostic molecular is quantitative reverse transcription PCR (qRT-PCR), which requires expensive equipment and trained personnel only available in limited laboratories. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is a one-step technology with fewer barriers to use than qRT-PCR; reagents are inexpensive and can be stored at room temperature, the technique works with a range of sample types, and it has been found to be highly specific, sensitive, and fast for other infectious diseases.

In the new study, researchers developed an RT-LAMP diagnostic test for SARS-CoV-2 and measured the effectiveness of the test on blood, urine, saliva and mouth swab samples that had been spiked with different amounts of SARS-CoV-2 genetic material. The test was also used on clinical samples from COVID-19 patients.

The RT-LAMP test for SARS-CoV-2 successfully detected the virus in all human sample types that were spiked with SARS-CoV-2 genetic material, within 30 to 45 minutes, with an estimated limit of detection of as few as 304 viral copies in a sample. Importantly, the test did not detect virus in samples spiked with RNA other coronaviruses, demonstrating specificity for SARS-CoV-2. In clinical mouth swab samples, RT-LAMP was positive for 95% (19/20) of samples positive by qRT-PCR and negative for 90% (18/20) of samples that were negative by qRT-PCR. The researchers note that those discrepancies between the methods could represent either false positives by the RT-LAMP, contamination or increased sensitivity of RT-LAMP compared to qRT-PCR. The current study was not powered to determine sensitivity in a clinical population.

Lamb summarizes: “This method can rapidly detect the virus for COVID-19 in clinical samples without expensive equipment.”

Source: PLOS

15.06.2020

Read all latest stories

Related articles

Photo

Digital health

AI test rules out Covid-19 diagnosis within one hour

An Artificial Intelligence test has been shown to be able to rapidly screen patients arriving in Emergency Departments for Covid-19, using clinical information routinely available within the first…

Photo

Collaboration with Mammoth Biosciences

Merck to scale up new SARS-CoV-2 Test

Merck announced a collaboration with Mammoth Biosciences Inc. for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test.

Photo

COVID-19

Novel viral transport media for testing of multiple infectious diseases

EKF Diagnostics, the global in vitro diagnostics company, announces that it has added a novel viral transport media for the safe sample handling and testing of multiple infectious diseases from a…

Related products

IBA Dosimetry – 2-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry – 2-part PMMA CT-Phantom

IBA Dosimetry GmbH
IBA Dosimetry – 3-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry – 3-part PMMA CT-Phantom

IBA Dosimetry GmbH
IBA Dosimetry – DIGI-13

Testing devices

IBA Dosimetry – DIGI-13

IBA Dosimetry GmbH
IBA Dosimetry – Dosimax plus A (HV)*

Testing Devices

IBA Dosimetry – Dosimax plus A (HV)*

IBA Dosimetry GmbH
IBA Dosimetry – Dosimax plus I

Testing Devices

IBA Dosimetry – Dosimax plus I

IBA Dosimetry GmbH
IBA Dosimetry – DSA Test Device

Testing Devices

IBA Dosimetry – DSA Test Device

IBA Dosimetry GmbH